Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Shanghai Yizhong Pharmaceutical (SHSE:688091) has had a rough three months with its share price down 34%. However, a closer look at its sound financials might cause you to think again. Given that fu
Shanghai Yizhong Pharmaceutical (SHSE:688091) Seems To Use Debt Rather Sparingly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems
Shanghai Yizhong (688091.SH) Performance Report: Net profit of 2023 was 163 million yuan, up 13.78% year-on-year
Gelonghui, Feb. 26: Shanghai Yizhong (688091.SH) announced the 2023 Annual Results Report. The company achieved operating revenue of 360 million yuan in 2023, an increase of 52.68% over the previous year. Net profit attributable to owners of the parent company was 163 million yuan, up 13.78% from the previous year; net profit attributable to owners of the parent company after deducting non-recurring profit and loss was 162 million yuan, an increase of 57.66% over the previous year.
Yizhong Pharmaceutical Starts Construction of Paclitaxel Polymer Micelles Production Facility; Shares Down 3%
Shanghai Yizhong Pharmaceutical (SHA:688091) started building a facility producing paclitaxel polymer micelles for injection after obtaining a construction license from the local government of China's
Shanghai Yizhong (688091.SH): “Construction of 5 million injectable paclitaxel polymer micelles and supporting facilities per year” has obtained a construction license for construction projects
Gelonghui, Feb. 4: Shanghai Yizhong (688091.SH) announced that it has recently obtained a “Construction Permit” issued by the Fengxian District Construction and Management Committee, marking that the “construction of 5 million injectable paclitaxel polymer micelles and supporting facilities per year” has entered the construction phase.
Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Stock Price Dropped 11% Last Week; Individual Investors Would Not Be Happy
Key Insights Shanghai Yizhong Pharmaceutical's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 7 shareholders
Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Yizhong Pharmaceutical Co., Ltd.'s SHSE:688091) Stock?
Shanghai Yizhong Pharmaceutical (SHSE:688091) has had a great run on the share market with its stock up by a significant 12% over the last month. Given the company's impressive performance, we decid
Shanghai Yizhong (688091.SH), the main shareholder of Shanghai Kaibao (), did not reduce its holdings at the end of the holdings reduction period
According to the Zhitong Finance App, Shanghai Yizhong (688091.SH) announced that Shanghai Kaibao Pharmaceutical Co., Ltd. (“Shanghai Kaibao”), which holds more than 5% of the company's shares, has not reduced its holdings in the company, and the current holdings reduction period has expired.
Shanghai Yizhong (688091.SH) released the first three quarter results, net profit of 131 million yuan, an increase of 25.40% over the previous year
Shanghai Yizhong (688091.SH) released its report for the third quarter of 2023. The company achieved revenue of 2 in the first three quarters...
Yizhong Pharmaceutical's Plant Passes Good Manufacturing Practice Inspection of Shanghai's Drug Regulator
Shanghai Yizhong Pharmaceutical's (SHA:688091) production line for paclitaxel polymer micelles for injection passed the good manufacturing practice compliance inspection of the drug administration of
Some shareholders of Shanghai Yizhong (688091.SH) completed a reduction of 162,000 shares
Shanghai Yizhong (688091.SH) announced that company shareholders Li Feng, Li Xun, and Xu Yuexiang reduced their holdings of the company's shares by a total of 16...
Individual Investors Are Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Biggest Owners and Were Hit After Market Cap Dropped CN¥489m
Key Insights Significant control over Shanghai Yizhong Pharmaceutical by individual investors implies that the general public has more power to influence management and governance-related decisions
Shanghai Yizhong (688091.SH): Director, Deputy General Manager, and Core Technician Sun Jing reduced her holdings by a total of 324,700 shares, and the time period for holdings reduction expires
Glonghui, Oct. 13, 丨 Shanghai Yizhong (688091.SH) announced that the company recently received the “Notification Letter on the Expiration of the Plan and the Results of the Reduction of Holdings” from Ms. Sun Jing, director, deputy general manager and core technician. As of October 9, 2023, Ms. Sun Jing had reduced her holdings of the company's shares by 324,700 shares through centralized bidding, accounting for 0.21% of the company's total share capital. The holdings reduction period has expired.
Shanghai Yizhong (688091.SH) will list and circulate approximately 1,582,800 restricted shares from September 11
According to the Zhitong Finance App, Shanghai Yizhong (688091.SH) announced that the restricted shares currently listed are the company's initial public offering of strategic placement restricted shares. The limited sale period is 24 months from the date the company's shares are listed. The number of shares that have been lifted from sale restrictions and applied for listing and circulation is about 1,582,800 shares, accounting for 1% of the company's total share capital. The number of shareholders involved is 1. This portion of the restricted shares will be listed and distributed from September 11, 2023.
Earnings Are Growing at Shanghai Yizhong Pharmaceutical (SHSE:688091) but Shareholders Still Don't Like Its Prospects
The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make higher profits, but you also face the risk of under-performance. Unfortunately
Shanghai Yizhong (688091.SH) plans to launch an incentive plan for 3 million restricted shares
Shanghai Yizhong (688091.SH) disclosed the 2023 Restricted Stock Incentive Plan (Draft) to 18...
Some shareholders of Shanghai Yizhong (688091.SH) reduced their holdings by a total of 132,700 shares
According to the Zhitong Finance App, Shanghai Yizhong (688091.SH) announced that the company's shareholders Li Feng, Li Xun, and Xu Yuexiang reduced their holdings of the company's shares by a total of 132,700 shares, accounting for 0.08% of the total share capital. The time for this holdings reduction plan is already over half.
Shanghai Yizhong (688091.SH): More than half of the time to reduce their holdings, Li Xun and Xu Yuexiang have reduced their holdings by a total of 0.08%
GLONGHUI, July 19丨Shanghai Yizhong (688091.SH) announced that as of July 19, 2023, Li Xun had reduced his holdings of the company's shares by a total of 21,329 shares through centralized bidding, accounting for 0.01% of the company's total share capital; Xu Yuexiang has reduced his holdings by 111,340 shares of the company's total share capital through centralized bidding, accounting for 0.07% of the company's total share capital; Li Feng has not reduced their holdings; the shareholders mentioned above have not reduced their holdings during the window period, etc. Halfway through the time of this holdings reduction plan, the implementation of the holdings reduction plan has not yet been completed.
Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
With its stock down 15% over the past three months, it is easy to disregard Shanghai Yizhong Pharmaceutical (SHSE:688091). But if you pay close attention, you might gather that its strong financials
Sun Jing, director of Shanghai Yizhong (688091.SH), reduced the company's holdings by a total of 249,700 shares
According to the Zhitong Finance App, Shanghai Yizhong (688091.SH) announced that as of July 7, Sun Jing, director, deputy general manager, and core technician, had reduced the company's shares by a total of 249,700 shares through centralized bidding, accounting for 0.16% of the company's total share capital. The amount of holdings reduced in this plan has been reduced by more than half, and the implementation of the holdings reduction plan has not yet been completed.
No Data